Abstract
Background and Purpose
Methods
Results
Notes
Conflicts of interest
The disclosures of conflicts of interest of all authors are provided in Appendix 1.
Author contribution
Conceptualization: SSE, AMS, SA. Study design: SSE, BFS, HM, KU, AMS, SA. Methodology: SSE, BFS, HM, KU, AMS, SA. Data collection: all authors. Investigation: all authors. Statistical analysis: SSE, HM, KU, AMS, SA. Writing—original draft: SSE, BFS, AMS, SA. Writing—review & editing: all authors. Funding acquisition: AMS. Approval of final manuscript: all authors.
ACKNOWLEDGMENTS
References
Table 1.
Data are expressed as median [interquartile range] or number of cases (%).
ASPECTS, Alberta Stroke Program Early Computed Tomography Score; ICA, internal carotid artery; M1, middle cerebral artery; mTICI, modified Thrombolysis in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; IV-tPA, intravenous tissue plasminogen activator; CTA, computed tomography angiography; CTP, computed tomography perfusion; DWI, diffusion-weighted imaging; ADAPT, A Direct Aspiration first Pass Technique; IAtPA, intra-arterial tissue plasminogen activator.
Table 2.
Outcome | mTICI 2c/3 (n=136) | mTICI 2b (n=98) | Crude OR (95% CI) | P | Adjusted OR* (95% CI) | P |
---|---|---|---|---|---|---|
mRS 0–3 | 60 (44.1) | 24 (24.5) | 2.43 (1.39–4.37) | <0.01 | 2.35 (1.18–4.81) | 0.02 |
mRS 0–2 | 30 (22.1) | 13 (13.3) | 1.85 (0.93–3.88) | 0.09 | 1.78 (0.77–4.31) | 0.20 |
Neurological improvement at 24 hours† | 59 (55.7) | 23 (34.8) | 2.35 (1.25–4.48) | <0.01 | 2.01 (1.04–4.28) | 0.04 |
Neurological improvement at discharge† | 65 (62.5) | 29 (43.3) | 2.18 (1.17–4.11) | 0.01 | 2.76 (1.31–6.01) | <0.01 |
Symptomatic intracranial hemorrhage | 20 (14.7) | 13 (13.5) | 1.10 (0.52–2.39) | 0.80 | 1.30 (0.58–3.04) | 0.60 |
Any hemorrhage | 55 (40.7) | 37 (38.5) | 1.10 (0.64–1.88) | 0.70 | 1.03 (0.57–1.85) | 0.70 |
Distal embolization | 15 (11.3) | 35 (38.0) | 0.21 (0.10–0.40) | <0.01 | 0.16 (0.07–0.34) | <0.01 |
90-Day mortality | 46 (33.8) | 41 (41.8) | 0.71 (0.42–1.22) | 0.20 | 0.68 (0.38–1.24) | 0.20 |
Data were expressed as number of cases (%), unless otherwise indicated.
ASPECTS, Alberta Stroke Program Early Computed Tomography Score; ICA, internal carotid artery; M1, middle cerebral artery; mTICI, modified Thrombolysis in Cerebral Infarction; OR, odds ratio; CI, confidence interval; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; IV-tPA, intravenous tissue plasminogen activator.
Table 3.
Outcome | mTICI 3 (n=103) | mTICI 2c (n=33) | Crude OR (95% CI) | P | Adjusted OR* (95% CI) | P |
---|---|---|---|---|---|---|
mRS 0–3 | 43 (41.7) | 17 (51.5) | 0.67 (0.30–1.48) | 0.30 | 1.01 (0.34–3.10) | >0.99 |
mRS 0–2 | 22 (21.4) | 8 (24.2) | 0.85 (0.35–2.24) | 0.70 | 0.84 (0.24–3.25) | 0.80 |
Neurological improvement at 24 hours† | 43 (54.4) | 16 (59.3) | 0.82 (0.33–1.98) | 0.70 | 1.03 (0.34–3.14) | >0.99 |
Neurological improvement at discharge† | 48 (59.3) | 17 (73.9) | 0.51 (0.17–1.38) | 0.20 | 0.39 (0.07–1.63) | 0.20 |
Any hemorrhage | 38 (37.3) | 17 (51.5) | 0.56 (0.25–1.23) | 0.15 | 0.46 (0.16–1.24) | 0.13 |
Symptomatic intracranial hemorrhage | 13 (12.6) | 7 (21.2) | 0.54 (0.20–1.55) | 0.20 | 0.36 (0.11–1.15) | 0.08 |
90-Day mortality | 37 (35.9) | 9 (27.3) | 1.49 (0.65–3.71) | 0.40 | 0.74 (0.24–2.28) | 0.60 |
Data were expressed as number of cases (%), unless otherwise indicated.
ASPECTS, Alberta Stroke Program Early Computed Tomography Score; ICA, internal carotid artery; M1, middle cerebral artery; mTICI, modified Thrombolysis in Cerebral Infarction; OR, odds ratio; CI, confidence interval; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; IV-tPA, intravenous tissue plasminogen activator.
Table 4.
mRS, modified Rankin Scale; OR, odds ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; mTICI, modified Thrombolysis in Cerebral Infarction; ASPECTS, Alberta Stroke Program Early Computed Tomography Score; IV-tPA, intravenous tissue plasminogen activator; ICA, internal carotid artery.